Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to investigate the information on safety and efficacy of naratriptan tablets on Japanese subjects with migraine headache during Japanese post-marketing surveillance period.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Naratriptan

Criteria

Inclusion Criteria:

• Subjects with migraine headache

• Must use naratriptan tablets for the first time

Exclusion Criteria:

• Subjects with hypersensitivity to naratriptan

• Subjects with history, symptoms, or signs of myocardial infarction, ischemic cardiac disease, or variant angina

• Subjects with history of peripheral vascular disorder

• Subjects with history of cerebrovascular disorder or transient ischemic attacks

• Subjects with uncontrolled high-blood pressure

• Subjects with severe hepatic function disorder or renal function disorder

• Subjects taking ergotamine, ergotamine derivative containing product, or 5-HT1B/1D agonist